Skip to content

The BRIDGES Project: Bridging Resources to Engage Women in Integrated HIV Care and Support Services

The BRIDGES Project: Bridging Resources to Engage Women in Integrated HIV Care and Support Services

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04295876
Acronym
BRIDGES
Enrollment
24
Registered
2020-03-05
Start date
2019-12-19
Completion date
2021-01-01
Last updated
2021-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Keywords

HIV Care Continuum, Ancillary Support Services

Brief summary

The BRIDGES Project seeks to test a program intended to help women living with HIV who face specific barriers due to culture, gender, violence, trauma, adverse mental health, and substance use to be able to better access HIV care. This program was created and tried with women living with HIV, as previously studies have indicated that women with these experiences are less likely to have stable HIV care. The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.

Detailed description

The BRIDGES Project intervention is culturally-tailored intervention for syndemic-affected cis- and transgender women living with HIV/AIDS (WLHA) that aims to: 1) build skills to cope with syndemic-related affective distress, 2) facilitate linkages to both HIV treatment and relevant ancillary service providers (e.g., domestic violence, mental health, substance use), and 3) teach women interpersonal skills to activate social support networks (e.g., service providers, friends, family) when faced with new or ongoing barriers. Participants in the The BRIDGES Project are estimated to demonstrate improvements in HIV care outcomes (i.e., linkage to HIV care, self-efficacy in ART adherence, retention in HIV care) and syndemic-support outcomes (i.e., coping skills, activated social support networks, linkage to and receipt of ancillary support services) compared to HIV-infected women assigned to standard of care (self-guided access and use of Ryan White case management).

Interventions

BEHAVIORALThe BRIDGES Project Intervention

The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.

Sponsors

Stanford University
CollaboratorOTHER
California HIV/AIDS Research Program
CollaboratorOTHER
University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Parallel intervention and control groups.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older * Identify as female, including cis-gender female or transgender female * Living with HIV/AIDS * Ability to speak and understand English * Self-report one or more syndemic factor(s) \[lifetime history of or current: trauma, physical violence and/or sexual violence, PTSD symptoms, substance use, adverse mental health\] * identification as one of the following: out-of-care or unstable in care, newly diagnosed, never in care, or linked to care but have fallen out of care\]

Design outcomes

Primary

MeasureTime frameDescription
Retention in Care6-months post-Baseline2 clinic visits 90+days apart, or as directed by an ART prescribing provider, assessed by medical record extraction
Linkage to Care3-months post-BaselineDocumentation of a clinical visit date with an ART-prescribing provider (yes, no), assessed by medical record extraction; days to first clinical visit since baseline (continuous), assessed by medical record extraction
Self-Efficacy for ART Adherence3-months post-BaselineValidated self-report measures of ART regime adherence
ART Initiation AND/OR Retention3-months post-BaselineValidated self-report measures of ART regime adherence

Secondary

MeasureTime frameDescription
Ancillary Support Service Access6-months post-BaselineSelf-Reported Support Service Access
Coping Self-Efficacy6-months post-BaselineValidated Measure of Coping Self-Efficacy (Coping Self Efficacy, Chesney et al 2006; Scale of 1 to 10 where 10 is greater coping self-efficacy.)
Social Support Network Activation6-months post-BaselineValidated Measure of Social Support, (MMOS-SS; Moser et al. 2012; Scale of 1 to 5 where 5 is greater social support.)
Ancillary Support Service Linkage3-months post-BaselineSelf-Reported Support Service Linkage

Other

MeasureTime frameDescription
ART Adherence6-months post-BaselineValidated self-report adherence measures, proportion of WLHA attaining HIV viral suppression (\<200 copies/mL, assessed by medical record extraction).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026